Stadium Capital Management Has Upped Its Position in Civitas Solutions (CIVI) by $681,372 as Market Value Declined; Eam Investors Has Lowered Its Portola Pharmaceuticals (PTLA) Position as Shares Rose

February 15, 2018 - By Vivian Currie

Eam Investors Llc decreased its stake in Portola Pharmaceuticals Inc. (PTLA) by 48.02% based on its latest 2017Q3 regulatory filing with the SEC. Eam Investors Llc sold 30,905 shares as the company’s stock rose 22.73% with the market. The institutional investor held 33,456 shares of the health care company at the end of 2017Q3, valued at $1.81M, down from 64,361 at the end of the previous reported quarter. Eam Investors Llc who had been investing in Portola Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $3.14B market cap company. The stock increased 1.97% or $0.93 during the last trading session, reaching $48.19. About 82,800 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 15, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Alexander Medina Seaver increased its stake in Civitas Solutions Inc (CIVI) by 2.34% based on its latest 2017Q3 regulatory filing with the SEC. Stadium Capital Management Llc bought 37,854 shares as the company’s stock declined 15.67% while stock markets rallied. The hedge fund run by Alexander Medina Seaver held 1.66 million shares of the health care company at the end of 2017Q3, valued at $30.60 million, up from 1.62 million at the end of the previous reported quarter. Stadium Capital Management Llc who had been investing in Civitas Solutions Inc for a number of months, seems to be bullish on the $486.23M market cap company. The stock increased 1.97% or $0.25 during the last trading session, reaching $12.95. About 16,448 shares traded. Civitas Solutions, Inc. (NYSE:CIVI) has declined 21.64% since February 15, 2017 and is downtrending. It has underperformed by 38.34% the S&P500.




Among 6 analysts covering Civitas Solutions (NYSE:CIVI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Civitas Solutions had 19 analyst reports since August 13, 2015 according to SRatingsIntel. SunTrust maintained Civitas Solutions, Inc. (NYSE:CIVI) rating on Wednesday, December 20. SunTrust has “Buy” rating and $21.0 target. The rating was maintained by Canaccord Genuity on Friday, February 9 with “Buy”. The firm has “Market Perform” rating given on Thursday, August 11 by Raymond James. The firm has “Buy” rating by Raymond James given on Friday, February 2. On Tuesday, December 12 the stock rating was maintained by Canaccord Genuity with “Buy”. On Thursday, November 19 the stock rating was downgraded by Raymond James to “Outperform”. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, September 16. The company was maintained on Wednesday, December 13 by Raymond James. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, January 6 report. The firm has “Buy” rating by Bank of America given on Friday, February 9.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on February, 27. They expect $-1.52 earnings per share, down 60.00% or $0.57 from last year’s $-0.95 per share. After $-1.41 actual earnings per share reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.80% negative EPS growth.

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 33 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, December 13 by Oppenheimer. The firm has “Buy” rating given on Friday, May 27 by Citigroup. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, December 27 report. The company was maintained on Monday, March 28 by Credit Suisse. Goldman Sachs downgraded Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Monday, March 28 to “Neutral” rating. The firm has “Overweight” rating by Morgan Stanley given on Friday, August 19. The rating was maintained by Cowen & Co on Wednesday, August 9 with “Buy”. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Thursday, December 28 by Oppenheimer. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Tuesday, December 19. Oppenheimer has “Buy” rating and $80.0 target. As per Thursday, August 10, the company rating was maintained by Oppenheimer.

Eam Investors Llc, which manages about $932.15M and $752.37 million US Long portfolio, upped its stake in Chegg Inc. (NYSE:CHGG) by 109,178 shares to 204,889 shares, valued at $3.04M in 2017Q3, according to the filing. It also increased its holding in Sodastream International Ltd. (NASDAQ:SODA) by 34,271 shares in the quarter, for a total of 100,397 shares, and has risen its stake in Silicom Ltd. (NASDAQ:SILC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.